These results seem promising in OI treatment but also indicate the need for further investigations on the use of this antibody in humans and on Losartan as an angiotensin II-receptor agent with anti-TGF-β properties [40,41]. The gene discussed is TGFB1; the disease is osteogenesis imperfecta.